Moderna Inc. (MRNA)
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.
Moderna Stock Price Target Slashed. It's About Vaccines.
The drug maker's shares have dropped 46% so far this year and 56% in the past three months.
Moderna Named a Top Employer by Science for Tenth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.
We Think Moderna Still Has A Future
Moderna, Inc.'s share price has weakened due to declining COVID-19 vaccine demand, but its diverse asset portfolio supports future growth and returns. The company is focusing on respiratory vaccines, including RSV, Flu, and COVID-19 variants, to sustain and grow its revenue streams. Despite massive R&D expenditures and significant losses, Moderna's development portfolio, including oncology and other vaccines, holds substantial long-term potential.
Why Moderna (MRNA) Dipped More Than Broader Market Today
Moderna (MRNA) reachead $53.80 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close.
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
Moderna (MRNA) concluded the recent trading session at $58.39, signifying a -0.56% move from its prior day's close.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna Lawsuit - MRNA
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
